We have located links that may give you full text access.
Journal Article
Review
Possibility of PD-1/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection.
Digestive Diseases 2023 October 12
Chronic hepatitis B (CHB) infection is still a major global public health problem, with nearly two billion patients. Although antiviral drugs can inhibit viral replication and reduce hepatitis B virus (HBV) related complications, it is difficult to achieve clinical endpoints due to drug resistance. Immune checkpoint inhibitors (ICIs) are an important strategy to reverse T-cell exhaustion, and rebuilding an effective functional T-cell response is a promising immunomodulatory approach for CHB patients. However, there are still many controversies in the application of ICIs in treating patients with CHB. This article reviews the research progress of ICIs in CHB infection and related issues.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app